1. Home
  2. Press release
Jun 03, 2022 16:37 JST

Source: Eisai

Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting

TOKYO, Jun 03, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.

Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).

"DAYVIGO continues to serve as an important asset to Eisai's neurology portfolio and we look forward to presenting the findings from several analyses at this year's SLEEP Meeting," said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. "Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,(1),(2) and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs."

(1) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10

About Lemborexant (product name: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.

For more information, visit www.eisai.com/news/2022/news202244.html.

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
More Press release >>

Latest Press Release


Mitani Sangyo Filed U.S. Patent Application for AI Reliability Governance Framework
Apr 17, 2026 00:00 JST

TANAKA PRECIOUS METAL NEXT Certified as a Special Subsidiary
Apr 16, 2026 21:00 JST

Isuzu and Toyota to Jointly Develop Japan's First Mass-produced Light-duty Fuel Cell Electric Truck
Apr 16, 2026 15:53 JST

Honda to Begin Sales of All-new Insight EV

Apr 16, 2026 15:31 JST

Hitachi Energy and Samsung C&T expand strategic collaboration to accelerate grid infrastructure and reinforce energy security
Apr 15, 2026 18:17 JST

Mitsubishi Motors' Outlander PHEV Ranks No. 1 in Japan's PHEV Sales Category for the Second Consecutive Year
Apr 15, 2026 18:01 JST

DENSO Establishes Strategic Partnership with Oracle to Modernize Core Supply Chain Systems
Apr 15, 2026 11:25 JST

Fujitsu and Chugoku Electric Power T&D sign IP licensing agreement to accelerate renewable energy integration and advance power transmission maintenance
Apr 15, 2026 11:07 JST

Seres Cements Luxury EV Leadership with Record Sales and RMB12.51 Billion R&D Investment
Apr 14, 2026 10:29 JST

Axonex Intelligence' AI Robotics Series Makes a Splash at InnoEX
Apr 13, 2026 19:33 JST

SuperX Japan Global Supply Center Completes First Batch Delivery, Marking Strategic Partnership Milestone in Japan
Apr 13, 2026 16:52 JST

Alpha Growth plc: Alpha Longevity Management launches U.S. specialty finance strategy for Japanese institutional investors, led by former members of Nikko Asset Management's team
Apr 13, 2026 16:00 JST

IFS and NEC to Deploy Next-Generation Core System IFS Cloud for Hoshizaki
Apr 10, 2026 10:10 JST

NEC's Automated Negotiation AI recognized as a Use Case in Gartner(R) Research
Apr 09, 2026 13:41 JST

Mitsubishi Motors Launches the Xforce in Malaysia
Apr 08, 2026 20:47 JST

MHI and Algomatic Win Second Place in the NEDO GENIAC-PRIZE Program
Apr 08, 2026 12:03 JST

MHI Receives Contract for Renewal of APM System ATL SkyTrain at Hartsfield-Jackson Atlanta International Airport
Apr 07, 2026 16:42 JST

JFE Holdings and Mitsubishi Corporation Sign Second MOU to Advance Integrated Power and Data Center Project in Ohgishima, Keihin District
Apr 06, 2026 14:27 JST

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Apr 03, 2026 12:33 JST

Hitachi Rail announces agreement to acquire Clever Devices, marking its growth as a global digital mobility player
Apr 03, 2026 11:09 JST
 More Latest Release >>